Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the SUMMIT trial (for tirzepatide) showed a reduction in events regarding time to cardiovascular death or worsening heart failure over 104 weeks (HR 0•62, 0•41-0•95), 79”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [79]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [30]
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“Tirzepatide also lowers CRP levels in clinical trials in people with heart failure with preserved ejection fraction, or OSA (19, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [66]
In the citing paper
“In the SUMMIT trial (Study of Tirzepatide in Participants With Heart Failure With Preserved Ejection Fraction and Obesity), tirzepatide reduced the risk of the composite of cardiovascular death and worsening HF events.23”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [23]
27 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Self-citationSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758
Self-citationPacker, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656
Self-citationTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF
Savji, N., Meijers, W. C., Bartz, T. M., Bhambhani, V., Cushman, M., Nayor, M., Kizer, J. R., Sarma, A., Blaha, M. J., Gansevoort, R. T., et al. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.05.018 · Cited by 499
Borlaug, B. A., Jensen, M. D., Kitzman, D. W., Lam, C. S. P., Obokata, M., & Rider, O. J. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac120 · Cited by 450
Self-citationPaulus, W. J., & Zile, M. R. (2021) · Circulation Research · doi:10.1161/circresaha.121.318159 · Cited by 393
Self-citationKosiborod, M. N., Deanfield, J., Pratley, R., Borlaug, B. A., Butler, J., Davies, M. J., Emerson, S. S., Kahn, S. E., Kitzman, D. W., Lingvay, I., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01643-x · Cited by 308
Self-citation
Cited by
Items 701–800 of 1,086
Bozkurt, B. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102631
Die ESC-Leitlinien zur Herzinsuffizienz im Spiegel aktueller Evidenz
Ghorani, H. A., Böhm, M., & Abdin, A. (2025) · Kardiologie up2date · doi:10.1055/a-2461-7287
de Macedo, R. R. B., Monteiro, F. V. D., Ribeiro, T. B., Santos, J. R. D., Santos, G. C. D., Costa, F. G., Silva, J. A. D. D., Barros, M. G. D., Santos, L. M. D., Barros, R. A., et al. (2025) · REVISTA ERR01 · doi:10.56238/err01v10n4-013
Carretero‐Gómez, J., Rodríguez, J. M. F., Doña, A. M., Miramontes‐González, J. P., Soler, J. J. G., Soto, M. I. P., Carrasco-Sánchez, F. J., Delgado, F., Arévalo‐Lorido, J. C., & Martínez, P. P. (2025) · Revista Clínica Española · doi:10.1016/j.rce.2025.502352
Tirzepatide and Gut Microbiome: A Narrative Review of Current Evidence and Future ImplicationsPreprint
Nandeesha, S. S., Biradar, S., Vasudeva, B., Yadav, V., & Bansal, S. (2025) · Preprints.org · doi:10.20944/preprints202509.1540.v1
Glucagon-like Peptide 1 Receptor Agonists and Risk of Pulmonary HypertensionPreprint
Garry, J. D., Kundu, S., Alcorn, C., Eden, S., Smith, E. K., Greevy, R. A., Tindle, H. A., Freiberg, M. S., & Brittain, E. L. (2025) · medRxiv · doi:10.1101/2025.09.18.25336100
Foster, M. W., Soueidy, A. A., Riley, J. M., Badenhausen, S. E., Naidu, S., Williams, N. N., Brailovsky, Y., Alvarez, R., Dumon, K. R., & Rame, J. E. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102674
Lateral Epidural Stimulation to Decrease Glucose Levels: A Preliminary Preclinical Study
Sokal, A., Chodakowski, P., Bogusz, A., Bogus, P., Eggen, M., Bhattacharya, A., & Kornet, L. (2025) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2025.08.409
Sex Differences in Cardiovascular-Related Responses to Obesity Treatment
Silver, N., Ghanta, A., Abene, J., Pinto, Y., & Chao, A. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00774-9
“[44 ] There was a statistically significant decrease in cardiovascular death or worsening heart failure, as well as an improvement in KCCQ-CSS scores between treatment and placebo.”
Heart Failure with Preserved Ejection Fraction Despite Normal Natriuretic Peptides
Lee, J. K., & Reddy, Y. N. V. (2025) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-025-01122-1
Malik, A., & Aleksova, N. (2025) · Canadian Cardiology Today · doi:10.58931/cct.2025.128
Phenotype-guided approach for device-based therapies in heart failure
Wattanachayakul, P., Kittipibul, V., Abraham, W. T., Hahn, R. T., Pinney, S., Desai, A. S., Burkhoff, D., & Fudim, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10565-4 · Cited by 1
“Despite recent advances in drug therapies [44, 45], device-based interventions are the alternatives for HFpEF management.”
Cardiovascular-kidney-metabolic-syndrome: a modern view of the problem
Кanorskiy, S. G. (2025) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2025-6-3-6-16
Effect of Tirzepatide on Cardiovascular Outcomes
Huston, J., Orey, D., Ashchi, A., Lachapelle, A. A., Genovese, A., Jackson, J., Ashchi, R., Ashchi, T., Ashchi, M., Sutton, D., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00767-4 · Cited by 1
“These findings support the potential role of tirzepatide in managing HFpEF, particularly in patients with coexisting obesity, where weight loss and inflammation reduction may contribute to improved cardiovascular outcomes [18, 19].”
InfluentialTARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE
Jędrzejewska-Rzezak, P., Żuczek, A., Dyndał, K., Broda, M., Żuczek, O., Urbańska, K., Szczap, I., Hawryluk, A., Marzec, K., & Mokrzycka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3902
Was ist gesichert in der medikamentösen Therapie der Herzinsuffizienz?
Soltani, S., & Bauersachs, J. K. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01998-y
Quarante ans d’avancées en cardiologie
Tedgui, A., & Taleb, S. (2025) · médecine/sciences · doi:10.1051/medsci/2025130
Eyadiel, L., & Modarressi, T. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.08.015
Adipokine Signaling in Heart Failure With Preserved Ejection Fraction
Mentz, R. J., & Oladuja, K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.045
Triozzi, J. L., Chen, H., Mamak, F., Yu, Z., Wilson, O. D., Ikizler, T. A., Ferolito, B. R., Cho, K., Gaziano, J. M., Tao, R., et al. (2025) · medRxiv · doi:10.1101/2025.10.13.25337903
Balla, S., Chakraborti, K., Jain, N., Ruske, J., & Shah, K. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.016
Soto, E. A. M., Araujo, J. E. G., Quezada, J. U. C., Carlos, I. O. M., Luna, P., Florez, Á. H. S., López, E. T., & Ortega, A. S. F. (2025) · IECCMEXICO · doi:10.64784/008
Sleep apnea at the frontier— an integrated multidisciplinary functional framework
Beache, G. M., Hutchinson, B., Raman, B., Macey, P. M., Pham, N., Lozano, P. F. R., Redeker, N. S., & Somers, V. K. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102190 · Cited by 1
TIRZEPATIDE FOR CARDIOVASCULAR RISK REDUCTION: A LITERATURE REVIEW
Settaf-Cherif, E., Settaf-Cherif, L., Malinowska, K., Barwacz, J., Gładysz, D., & Adamik, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3989
“Moreover, patients reported improvements in quality of life (mean increase in KCCQ-CSS of 6.9 points) and exercise capacity (mean increase of 19m in the 6-minute walk test) while experiencing around 11-12% weight loss and reduced inflammation (hs-CRP)(Packer et al., 2025).”
InfluentialVainer, D., SIMONETTI, J. S., Pham, T. A., & Khor, L. L. C. (2025) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001881
Zidek, W. (2025) · Diabetes aktuell · doi:10.1055/a-2624-1018
“Herzin-suffizienz mit erhaltener Ejektionsfraktion [6, 7].”
Zile, M. R., Borlaug, B. A., Kramer, C. M., & Packer, M. (2025) · Circulation · doi:10.1161/circulationaha.125.075872
Self-citationTirzepatid bei Herzinsuffizienz mit erhaltener Ejektionsfraktion und Adipositas
Lorenz, J. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2546-0975
Lanier, A., Lutolli, F., & Belkin, M. N. (2025) · ESC Heart Failure · doi:10.1002/ehf2.70015
Looking AHEAD to Heart Failure Prevention
Hahn, V. S., Grant, J. K., & Ndumele, C. E. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102732
Heart failure: focus on genes, kidney, and sudden death
Crea, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf872
Sim, D., Lin, W., Teo, L. L. Y., Prameswari, H. S., Wong, Y. M., Mebazaa, A., Bader, F. M., Sindone, A. P., Ghazi, A. M., Zhang, Y., et al. (2025) · Journal of Asian Pacific Society of Cardiology · doi:10.15420/japsc.2025.31
Glucagon-Like Peptide-1 Receptor Agonists
Whitley, H. P. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch13
El valor social de un mejor control de la obesidad en España
(2025) · Fundación Weber eBooks · doi:10.37666/i30-2025 · Cited by 1
Severe Infections as a Novel Risk‐Enhancing Factor for Incident Heart Failure
Demmer, R. T., Grossardt, B. R., Khan, S. S., & Borlaug, B. A. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047537
Self-citationGLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.10.24 · Cited by 1
Confronting the Global Rise of Obesity and Cardiovascular Disease
Spatz, E. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1599
Picinin, V. D., Balbinott, L. T., Spolaor, A., & Barachini, A. P. (2025) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i2.2025.1731
Nutrient-Stimulated Hormone-Based Therapies: Transforming Obesity Management
Kwak, K. H., & Jung, C. H. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2803 · Cited by 1
“…cardiovascular events in patients with obesity [14], and emerging evidence suggests that semaglutide and tirzepatide may provide additional benefits for heart failure (HF), particularly HF with preserved ejection fraction [15], and MASLD/metabolic dysfunction-associated steatohepatitis (MASH) [16].”
Systemic benefits of weight loss: impact on cardiovascular risk
Tozzi, R. (2025) · The Journal of AMD · doi:10.36171/jamd25.28.3.15
Nuevo algoritmo de redGDPS 2026: de la glucemia al paciente
Soidán, F. J. G., Menéndez, S. A., Lachica, L. Á., Pato, Ó. B., Pradas, N. C., Teixidó, C. H., Vela, N. S., Mera-Gallego, I., & Carretero-Anibarro, E. (2025) · Diabetes práctica · doi:10.52102/diabet/pract.2025.4.art2 · Cited by 1
Marx-Schütt, K., Forst, T. M., Birkenfeld, A. L., Zirlik, A., Müller‐Wieland, D., & Marx, N. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8456
Explanation of JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure (2)
Sezai, A., Tanaka, M., Kitano, D., & Okumura, Y. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.6_245
Lim, P. O. (2025) · Springer eBooks · doi:10.1007/978-3-032-10734-3_3
Melro, A. C. C., Damaceno, G. M., de Sousa, L. A., Neri, D. N., Fuchs, L. C., Polate, A. T., Azevedo, E. C., Neglisoli, V., Buller, L. H. N., Marinho, M. D. F. L., et al. (2026) · Seven Editora eBooks · doi:10.56238/sevened2026.009-001
Bhaduri, G., BHATTACHARYYA, S., Mukherjee, S., & Gokalani, R. A. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02636-7
Epicardial Fat is Associated with Ventricular Dilation in Patients After the Fontan Operation
Ryan, M. E., Clair, N. S., Lee, C. K., & Rathod, R. H. (2026) · Pediatric Cardiology · doi:10.1007/s00246-025-04148-1
“Further, glucagon-like peptide-1 (GLP-1) have demonstrated improved cardiovascular outcomes in adult patients with heart failure and obesity [30].”
Tomović, S., Miljković, N., Bogović, A., Smiljković, T., Dedić, S., Boskovic, N., Ostojic, M., Ristić, M., Giga, V. L., Nedeljković, I., et al. (2024) · Srce i krvni sudovi · doi:10.5937/siks2404110t
Siddiqi, T. J., Khan, M. M., Fonarow, G. C., Butler, J., & Greene, S. J. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuaf004
Malmborg, M. W., El-Chouli, M. H., Andersen, C. F., Elmegaard, M., Garred, C. H., Zahir, D., Butt, J. H., Christensen, D. M., Nouhravesh, N., Fosbøl, E. L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03062-3
“Associations between body mass index, treated as a continuous variable, and the primary and secondary outcomes using restricted cubic splines in Cox proportional-hazards models.”
Pathogenesis and Therapeutic Advances in Heart Failure with Preserved Ejection Fraction
Fan, X., Ma, J., Zhao, X., & Yu, J. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm45613 · Cited by 1
“The SUMMIT trial indicated that the dual GIP/GLP-1 receptor agonist tirzepatide improved quality of life and reduced the risk of cardiovascular death or worsening heart failure in patients with HFpEF [65].”
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Iglesias, P. C. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02828-0
Glucagon-like Peptide-1 Receptor Agonists
Kligman, M., & Holsten, S. B. (2026) · Surgical Clinics of North America · doi:10.1016/j.suc.2025.12.011
Melro, A. C. C., Filho, M. J. D. C., Queiroz, B. S. F. D., Bezerra, D. C., Venegas, Y. E., Barbosa, C. S., Júnior, M. C. D. S., Costa, F. J. M. C. D., Schlottfeldt, D. G., Silva, A., et al. (2026) · Congresso Nacional de Medicina · doi:10.56238/medcientifica-086
Marx-Schütt, K., Forst, T. M., Birkenfeld, A. L., Zirlik, A., Müller‐Wieland, D., & Marx, N. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01426-1
GLP-1 Receptor Agonists: Emerging Indications, Limitations, and Future Directions
Kaur, S., Hevia, L. C., Lee, D., Mesdaq, H., Wong, J., Diallo, F., Anil, S., Gharibyar, N., & Gharibyar, S. (2026) · Pharmacology & Pharmacy · doi:10.4236/pp.2026.172003
Oliveira-Gomes, D. D., de Majo, A. M., Ardila-Delgado, A. D., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01395-2
“Tirzepatide (up to 15 mg subcutaneously once per week) reduced the composite of CV death or worsening heart fail - ure events (9.9% vs. 15.3%; HR 0.62), demonstrating not only reductions in weight but also improvements in clinical outcomes and patient-reported quality of life [ 44].”
InfluentialBeyond BMI: why heart failure trials must quantify adiposity, not just obesity
Bayés‐Genís, A., & Schiattarella, G. G. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag046
Do we need exercise echocardiography to diagnose HFpEF? Not at all
Brennan, A. C., Campbell, R., Docherty, K. F., Lee, M. M. Y., McMurray, J. J. V., Cleland, J. G. F., Petrie, M. C., & Pellicori, P. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag044
Rodríguez, J. M. F., Ortiz, M. B. A., Casado, J., Chivite, D., Romano, P. C., Alonso, R. G., Almorós, A. L., Miramontes‐González, J. P., Rangel, L. S., & Pérez-Silvestre, J. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502471
Shokravi, A., Singh, R., Sharma, S., Seth, J., & Mancini, G. B. J. (2026) · CJC Open · doi:10.1016/j.cjco.2026.02.008 · Cited by 1
“8 Although EXSCEL did not include a BMI cutoff, 26 the mean BMI was > 30 kg/m 2 , and SELECT enrolled a mix of overweight and obese participants.”
Bariatric surgery in the era of modern obesity pharmacotherapy
Zhao, A. Y., & Dash, S. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag004
Medikamentöse Therapie der Adipositas
Malzner, A. (2026) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-026-00250-0
McGuigan, A. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-026-01226-z
“Tirzepatide is a GLP-1RA combined with a glucose-dependent insulinotropic polypeptide receptor agonist [28].”
Treatment Decision-making and Weight Loss Expectations for Current Obesity Treatment
Paknikar, S. S., & Shah, M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00691-x
Chang, K.-C., Lin, K.-Y., Kuan, D. T.-W., Huang, K.-C., Lin, T. T., Wu, C., Lin, L., & Lin, L.-Y. (2026) · Hypertension Research · doi:10.1038/s41440-026-02584-x
Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
Sattar, N. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00013-6
2025 Nutrition Science & Communications Forum: Summary
Steiber, A. L., Paulsen, E., & Brown, N. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156324
Costa, T. A., Vest, A. R., & Harrington, J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001284
Diagnostik und Therapieansätze der Herzinsuffizienz mit erhaltener systolischer Funktion
Beyer, M., Mügge, A., Akın, İ., van Heerebeek, L., El‐Battrawy, I., & Hamdani, N. (2026) · Die Kardiologie · doi:10.1007/s12181-026-00807-6
How difficult is the diagnosis of heart failure with preserved ejection fraction
Cesari, A., Sacco, A., & Oliva, F. G. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag040
Cardio-renal-metabolic syndrome and its management in clinical practice
Šatný, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.091
Grossmann, E., Schilling, H., & Magnussen, C. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00751-2
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Quantifying myocardial oxygen consumption and efficiency with motion-resolved cardiac MRI
Huang, L.-T., Yang, C., Wang, G., Zhang, H., Zhang, R., Ho, H. H., Malagi, A., Huang, Y., Li, X., Yoosefian, G., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.ady6269
Khalil, I., Hossain, I., Sarker, P., Nur, N., Al-Badri, S. G., Akter, M. M., Halder, L., Rahman, M. T., & Kamrul-Hasan, A. B. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.03.009
Obesity Management and Cardiovascular Risk Reduction: from Tradition to Innovation
Costa, T. A., Harrington, J., Nelson, A. J., Pandey, A., Neeland, I. J., Lee, M. M. Y., Kang, Y. M., & McGuire, D. K. (2026) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-026-01138-1
Advances in Cardiorenal Medicine: The Year 2025 in Review
Kazory, A., & Ronco, C. (2026) · Cardiorenal Medicine · doi:10.1159/000551756
Riesemann, S., Tenge, T., & Roth, S. (2026) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001644
Sillassen, C. D. B., Faltermeier, P., Bjerg, J. L., Andersen, R. K., Petersen, J. J., Andersen, P. B., Kamp, C. B., Karlsson, F., Grand, J., Domínguez, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04824-w · Cited by 3
“1 [3, 15–17 ,”
InfluentialKartiko, D. C., Rejeki, P. S., Indarto, D., Subagio, I., Hartati, S. C. Y., Orhan, B. E., Nurwati, Y., & Pranoto, A. (2026) · Physical Education Theory and Methodology · doi:10.17309/tmfv.2026.2.16
“Given the increasing burden of obesity-related comorbidities, including cardiovascular and hepatic complications (Packer et al., 2025; Younossi et al., 2025; European”
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“It also seems to reduce mortality and worsening of HF in patients affected by obesity and HF with preserved ejection fraction (HFpEF) [37].”
Finerenone in heart failure with ejection fraction ≥40%: state of the art and future perspectives
Llàcer, P., Marcos, M. C., Núñez, J. E., Perez-Belmonte, L. M., Pérez-Silvestre, J., Martéles, M. S., & Colet, J. C. (2026) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2026.502520
Cardiovascular pharmacotherapy in 2025
Tamargo, J. L., Agewall, S., Ambrosio, G., Borghi, C., Cerbai, E., Dan, G., Drexel, H., Ferdinandy, P., Grove, E. L., Klingenberg, R., et al. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag016 · Cited by 2
“13 The effect of tirzepatide was consistent in all subgroups and was associated with similarly decreased LV-mass and visceral adiposity (paracardiac fat) in patients with and without T2D.”
Phillippi, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00173-4
Sztefka, D., Jaunich, A., Szlachetka, K., & Zając, A. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.5402
“Tirzepatide, as a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist, represents a newer therapeutic option for patients with a pronounced metabolic phenotype, especially obesity and HFpEF (Packer et al., 2025).”
InfluentialHeart Failure With Preserved Ejection Fraction
Weigel, F., & Miller, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00188-6
Managing patients with heart failure: A contemporary practice tool for pharmacists
Barry, A. R., & Koshman, S. L. (2026) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3138/cpj-25-0119
Llàcer, P., Marcos, M. C., Nuñez, J., Perez-Belmonte, L. M., Pérez-Silvestre, J., Marteles, M. S., & Colet, J. C. (2026) · Revista Clínica Española · doi:10.1016/j.rce.2026.502520
Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults
Toma, L., Buckley, K. D., & Early, N. K. (2026) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2026.78
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20260056
Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie
Busti, M. D., Canonico, M. E., Keramida, K., Palazzuoli, A., Kato, E. T., Sakata, Y., Alexy, T., Grupper, A., Nodari, S., Ojji, D. B., et al. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10627-1
Obesity and the Obesity Paradox in Heart Failure
Koos, A., Vyas, A., Catalfamo, V. J., Tutor, A. W., & Lavie, C. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00177-1
Combination of prolonged water fasting and GLP-1 for refractory morbid obesity: Case report
Palmisano, T., Roeschenthaler, P., Passerini, H., Shin, T., & Guarraia, D. (2026) · European Journal of Clinical Nutrition · doi:10.1038/s41430-026-01749-8
Brandenburg, V. (2026) · Nephrologie aktuell · doi:10.1055/a-2748-5190
Worsening heart failure–based hierarchical endpoints beyond HF hospitalization: expert opinion paper
Cisnal, A. F., Miñana, G., de la Espriella, R., Santas, E., Trullàs, J. C., Biegus, J., Spall, H. G. C. V., & Núñez, J. E. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag107
Cho, D. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0002
“12) 13-15 This review synthesizes the evolving role of NuSH in HF, exploring the transition from weight management to cardiovascular protection, and discusses the remaining challenges and future perspectives in this rapidly advancing field.”
Beyond phenogroups: towards a continuous biology of HFpEF
Störk, S., & Shimokawa, H. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag130
Metadata
- Authors
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., & Borlaug, B. A.
- Affiliations
- Cleveland Clinic (US)
- From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiovascular Division, Department of Medicine, University of Virginia Health System, Charlottesville (C.M.K.); Flourish Research, Boca Raton, FL (S.J.B.); the Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland (V.M.); the Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China (J.G.); Eli Lilly, Indianapolis (G.J.W., Y.O., M.C.B., K.C.H., M.M.); and the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-01-30
- Volume
- 392
- Issue
- 5
- Pages
- 427-437
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404437149
- Semantic Scholar
- aeedfcfb5543cef26bd4f4576e1c5a59b4d2424f
- Cited by
- 1,009
- References
- 30
- Citations by year
- 2026: 496 · 2025: 494
- FWCI
- 303.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company (N/A)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, heart failure with preserved ejection fraction, obesity, GIP/GLP-1 receptor agonist, weight loss, cardiovascular mortality, worsening heart failure, Kansas City Cardiomyopathy Questionnaire, quality of life, body mass index, GLP-1 receptor agonists, GIP receptor agonist, cardiovascular outcomes, weight loss treatment, heart failure with reduced ejection fraction
- MeSH terms
- Tirzepatide, Aged, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Humans, Male, Middle Aged, Obesity, Quality of Life, Stroke Volume, Weight Loss, Body Mass Index, Treatment Outcome, Glucagon-Like Peptide 1, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.